Moneycontrol
Last Updated : Sep 22, 2018 03:10 PM IST | Source: Moneycontrol.com

Biocon's Bengaluru drug substance facility clears USFDA audit with zero observations

The current good manufacturing practices (cGMP) inspection took place from September 17 to 21

Moneycontrol News @moneycontrolcom
Representative Image
Representative Image
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Biocon on Saturday said it has underwent US FDA audit of its Bengaluru API drug substance manufacturing facility in Bengaluru without any observations.

The current good manufacturing practices (cGMP) inspection took place from September 17 to 21. The facility makes active ingredients for both formulations and biologic drugs.

The weeklong audit concluded without any observations and no Form 483 was issued.

"The successful audit of this site reflects our strong commitment tocGMP compliance," Biocon said in a statement.
First Published on Sep 22, 2018 03:10 pm
Loading...
Sections
Follow us on
Available On